HIV Therapeutics Utilizing Peptide Secreting Commensal Bacteria
Posted Jan 17 2012 7:00pm
Description of Invention: Available for licensing and commercial development is a patent estate covering genetically engineered commensal bacteria compositions and their methods of use that secrete HIV infectivity interfering peptides with the aid of co-expressed translocation mediators such as HylB, HylD or tolC gene products. The bacteria can be, for example, Escherichia coli, and are preferably those that colonize the gastrointestinal or genitourinary tracts. The secreted anti-HIV peptide can be a functional inhibitory fragment from the C-terminus of HIV, SHIV or SIV, or an inhibitory peptide derived from the N-terminus receptor-binding domain of SIV gp41, HIV-1 gp41, or HIV-2 gp41. The secreted anti-HIV peptide can also be a peptide from the allosteric domain of gp120, an extracellular loop of CCR5, an anti-CD4 immunoglobulin, a mimetic of CD4, an alpha-defensin or theta-defensin, a CD38 fragment homologous to the V3 loop of gp120, polphemusin II (a CXCR4 antagonist), a RANTES peptide that binds to CCR5 or an HIV surface binding peptide such as cyanovirin.
For Licensing Information Please Contact: Michael Shmilovich Esq. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: shmilovm@mail.nih.gov Phone: 301-435-5019 Fax: 301-402-0220
Description of Invention:
Available for licensing and commercial development is a patent estate covering genetically engineered commensal bacteria compositions and their methods of use that secrete HIV infectivity interfering peptides with the aid of co-expressed translocation mediators such as HylB, HylD or tolC gene products. The bacteria can be, for example, Escherichia coli, and are preferably those that colonize the gastrointestinal or genitourinary tracts. The secreted anti-HIV peptide can be a functional inhibitory fragment from the C-terminus of HIV, SHIV or SIV, or an inhibitory peptide derived from the N-terminus receptor-binding domain of SIV gp41, HIV-1 gp41, or HIV-2 gp41. The secreted anti-HIV peptide can also be a peptide from the allosteric domain of gp120, an extracellular loop of CCR5, an anti-CD4 immunoglobulin, a mimetic of CD4, an alpha-defensin or theta-defensin, a CD38 fragment homologous to the V3 loop of gp120, polphemusin II (a CXCR4 antagonist), a RANTES peptide that binds to CCR5 or an HIV surface binding peptide such as cyanovirin.
Applications:
HIV therapeutics
Advantages:
Utilizes naturally occurring commensal bacteria
Development Status:
Inventors:
Dean H Hamer (NCI)
Patent Status:
HHS, Reference No. E-233-2004/0
US, Application No. 11/710,512 filed 26 Feb 2007
PCT, Application No. PCT/US2005/030216 filed 25 Aug 2005
and various international issued patents
Relevant Publication:
For Licensing Information Please Contact:
Michael Shmilovich Esq.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: shmilovm@mail.nih.gov
Phone: 301-435-5019
Fax: 301-402-0220
Ref No: 1000
Updated: 01/2012